ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

  • STATUS
    Recruiting
  • End date
    May 21, 2026
  • participants needed
    870
  • sponsor
    Prof. Dr. M. Dreyling (co-chairman)
Updated on 23 February 2022
total body irradiation
cyclophosphamide
cytarabine
rituximab
filgrastim
vincristine
granulocyte colony stimulating factor
melphalan
prednisone
measurable disease
etoposide
dexamethasone
ara-c
neutrophil count
mantle cell lymphoma
r-chop
ibrutinib
bone marrow infiltration
chop regimen

Summary

The primary objective of the the trial is to establish one of three study arms, as future standard based on the comparison of the investigator-assessed failure-free survival.

Description

Objectives and Endpoints

Primary Objective:

To establish one of three study arms, R-CHOP/R-DHAP followed by ASCT (control arm A), R-CHOP+ibrutinib /R-DHAP followed by ASCT and ibrutinib maintenance experimental arm A+I), and R-CHOP+ibrutinib /R-DHAP followed by ibrutinib maintenance experimental arm I) as future standard based on the comparison of the investigator-assessed failure-free survival (FFS).

Secondary Objectives:

  • To compare the efficacy of the three treatment arms in terms of secondary efficacy endpoints
  • To determine the safety and tolerability of ibrutinib during induction immuno-chemotherapy and during maintenance and to compare the safety profile of the three treatment arms in terms of secondary toxicity endpoints

Primary Endpoint:

FFS defined as time from start of treatment to stable disease at end of immuno-chemotherapy, progressive disease, or death from any cause.

Secondary Efficacy Endpoints:

  • Overall survival (OS)
  • Progression-free survival (PFS) from randomization, from end of induction immuno-chemotherapy in patients with CR or PR at end of induction immuno-chemotherapy, and from the staging 6 weeks after end of induction assessment (at month 6)
  • Overall response and complete remission rates at midterm, at end of induction, 3 months after end of induction immunochemotherapy (at month 6)
  • PR to CR conversion rate during follow-up after end of induction immuno-chemotherapy

Secondary Toxicity Endpoints:

  • Rates of AEs, SAEs, and SUSARs by CTC grade (Version 4.03) during induction immuno-chemotherapy and during periods of follow-up after response to immune-chemotherapy
  • Cumulative incidence rates of SPMs

Exploratory Objectives:

  • To compare feasibility of ASCT in arm A+I vs. arm A
  • To compare minimal residual disease status between the three treatment groups
  • To determine the impact of ibrutinib during induction immuno-chemotherapy and during maintenance therapy on the minimal residual disease status
  • To determine the prognostic value of minimal residual disease status
  • To determine the prognostic value of positron emission tomography with fluorine 18-fluorodeoxyglucose
  • To determine clinical and biological prognostic and predictive factors
  • To determine the role of total body irradiation (TBI) in ASCT conditioning

Exploratory Endpoints:

  • Rate of successful stem cell mobilisations (success: separation of at least 2x2x10(6) CD34-positive cells, including a back-up)
  • Rate of molecular remissions (MRD-negative patients) at midterm, at end of induction immuno-chemotherapy, and at staging time-points during follow-up in patients with remission after end of induction immuno-chemotherapy
  • Time to molecular remission from start of therapy
  • Time to molecular relapse for patients in clinical and molecular remission after end of induction immunochemotherapy
  • RD in FDG-PET negative or positive patients after induction and ASCT

Exploratory objectives may be evaluated only in a subset of patients according to local standards and resources.

Details
Condition Mantle Cell Lymphoma
Treatment R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT conditioning, Ibrutinib (Maintenance)
Clinical Study IdentifierNCT02858258
SponsorProf. Dr. M. Dreyling (co-chairman)
Last Modified on23 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

All patients must meet the following criteria
Histologically confirmed diagnosis of MCL according to WHO classification
suitable for high-dose treatment including high-dose Ara-C
Stage II-IV (Ann Arbor)
Age 18 years and 65 years
Previously untreated MCL
At least 1 measurable lesion; in case of bone marrow infiltration only, bone marrow aspiration and biopsy is mandatory for all staging evaluations
ECOG/WHO performance status 2
The following laboratory values at screening (unless related to MCL)
Absolute neutrophil count (ANC) 1000 cells/L
Platelets 100,000 cells/L
Transaminases (AST and ALT) 3 x upper limit of normal (ULN)
Total bilirubin 2 x ULN unless due to known Morbus Meulengracht [Gilbert-Meulengracht-Syndrome])
Creatinine 2 mg/dL or calculated creatinine clearance 50 mL/min
Written informed consent form according to ICH/EU GCP and national regulations
Sexually active men and women of child-bearing potential must agree to use highly effective contraceptives (eg, condoms, implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence, or sterilized partner) while on study; this should be maintained for 90 days after the last dose of study drug

Exclusion Criteria

Any potential subject who meets any of the following criteria will be excluded
from participating in the study
Major surgery within 4 weeks prior to randomization
Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg phenprocoumon)
History of stroke or intracranial hemorrhage within 6 months prior to randomization
Requires treatment with strong CYP3A4/5 inhibitors
Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization
Known CNS involvement of MCL
Clinically significant hypersensitivity (eg, anaphylactic or anaphylactoid reactions to the compound of ibrutinib itself or to the excipients in its formulation)
Known anti-murine antibody (HAMA) reactivity or known hypersensitivity to murine antibodies
Previous lymphoma therapy with radiation, cytostatic drugs, anti-CD20 antibody or interferon except prephase therapy according to trial protocol
Serious concomitant disease interfering with a regular therapy according to the study
protocol
Cardiac (Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification or LVEF below LLN )
Pulmonary (e.g. chronic lung disease with hypoxemia)
Endocrinological (e.g. severe, not sufficiently controlled diabetes mellitus)
Renal insufficiency (unless caused by the lymphoma): creatinine > 2x normal value and/or creatinin clearance < 50 ml/min)
Impairment of liver function (unless caused by the lymphoma): transaminases > 3x normal or bilirubin > 2,0 mg/dl unless due to morbus Meulengracht (Gilbert-Meulengracht-Syndrome)
Patients with unresolved hepatitis B or C infection or known HIV positive infection (mandatory test)
Prior organ, bone marrow or peripheral blood stem cell transplantation
Concomitant or previous malignancies within the last 3 years other than basal cell skin cancer or in situ uterine cervix cancer
Pregnancy or lactation
Any psychological, familiar, sociological, or geographical condition potentially hampering compliance with the study protocol and follow up schedule
Subjects not able to give consent
Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial
Participation in another clinical trial within 30 days before randomization in this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note